Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Inhibitors of factor VIII: detection and treatment

Brettler, D.B.

Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 21-25

1993

ISSN/ISBN: 0125-1562
PMID: 7886576
Document Number: 6997
Alloantibodies occurring in hemophiliacs is a side effect or repeated treatment and represents a severe complication. The induction of immune tolerance using one of the lower dose regimens should be attempted as soon as it is feasible as regimens started soon after the inhibitor appears may have greater success in inducing tolerance. If the hemophiliac with inhibitor hemorrhages, PCC for aPCC should be the first line of therapy since these concentrates can be given in the home setting. If the hemorrhage is severe and the anti-porcine inhibitor titer is low, the patient should be infused in a clinic or hospital setting with porcine factor VIII using increasing doses to achieve a circulating factor VIII level. Entry into clinical trials, such as those using rFVIIa should be encouraged.

Document emailed within 1 workday
Secure & encrypted payments

Inhibitors of factor VIII: detection and treatment

Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Johannessen, M.; Andreasen, R.B.; Nordfang, O. 2000: Decline of factor VIIi and factor IX inhibitors during long-term treatment with NovoSeven Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 11(3): 239-242
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Lusher, J.M.; Eyster, M.E.; Hilgartner, M.W.; Kasper, C.K.; Mannucci, P.M.; Nilsson, I.M.; Penner, J.A.; Roberts, H.R. 1984: Panel discussion on the treatment of patients with factor VIII inhibitors Progress in Clinical and Biological Research 150: 323-335
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Aznar, J.A.; Jorquera, J.I.; Peiró, A.; Garcia, I. 1984: The importance of corticoids added to continued treatment with Factor VIIi concentrates in the suppression of inhibitors in haemophilia a Thrombosis and Haemostasis 51(2): 217-221
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Hay, C.R.; Colvin, B.T.; Ludlam, C.A.; Hill, F.G.; Preston, F.E. 1996: Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 7(2): 134-138
Hauser, I.; Schneider, B.; Lechner, K. 1995: Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment Thrombosis and Haemostasis 73(1): 1-5
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Mahasandana, C.; Patharathienskul, D.; Suvatte, V. 1993: Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 106-112
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551
Ruggeri, Z.M.; Bader, R.; Coppola, R.; Mannuccio Mannucci, P. 1977: Factor VIIi inhibitors La Ricerca in Clinica e in Laboratorio 7(Suppl 2): 17-29
Travis, P.A.; Bovill, E.G.; Hamill, B.; Tindle, B.H. 1988: Detection of factor VIIi von Willebrand factor in endothelial cells in first-trimester fetuses Archives of Pathology and Laboratory Medicine 112(1): 40-42
Lutze, G.; Schlote, A.; Mittler, U. 1980: Determination of coagulation factor VIIi inhibitors Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 35(8): 330-336
Green, D. 1994: Immunosuppression of patients with acquired factor VIIi inhibitors Seminars in Hematology 31(2 Suppl 4: 60-61
Goldsmith, J.C. 1993: Diagnosis of factor VIIi versus nonspecific inhibitors Seminars in Hematology 30(2 Suppl 1: 3-6
Iizuka, A.; Kuwashima, M.; Nagao, T. 1982: Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIIi or IX Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 45(5): 987-992
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68